JP2008532936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008532936A5 JP2008532936A5 JP2007555332A JP2007555332A JP2008532936A5 JP 2008532936 A5 JP2008532936 A5 JP 2008532936A5 JP 2007555332 A JP2007555332 A JP 2007555332A JP 2007555332 A JP2007555332 A JP 2007555332A JP 2008532936 A5 JP2008532936 A5 JP 2008532936A5
- Authority
- JP
- Japan
- Prior art keywords
- signaling
- heterodimer
- protein
- seq
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108050003558 Interleukin-17 Proteins 0.000 claims description 198
- 102000013691 Interleukin-17 Human genes 0.000 claims description 197
- 230000011664 signaling Effects 0.000 claims description 47
- 239000005557 antagonist Substances 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000012646 vaccine adjuvant Substances 0.000 claims description 4
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 4
- 239000013566 allergen Substances 0.000 claims description 2
- 230000000961 alloantigen Effects 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 45
- 239000000833 heterodimer Substances 0.000 claims 36
- 238000000034 method Methods 0.000 claims 29
- 108091033319 polynucleotide Proteins 0.000 claims 25
- 102000040430 polynucleotide Human genes 0.000 claims 25
- 239000002157 polynucleotide Substances 0.000 claims 25
- 239000000710 homodimer Substances 0.000 claims 23
- 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 claims 20
- 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 claims 19
- 101710186068 Interleukin-17 receptor C Proteins 0.000 claims 15
- 102100035012 Interleukin-17 receptor C Human genes 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 239000000523 sample Substances 0.000 claims 12
- 239000002773 nucleotide Substances 0.000 claims 11
- 125000003729 nucleotide group Chemical group 0.000 claims 11
- 102000037865 fusion proteins Human genes 0.000 claims 10
- 108020001507 fusion proteins Proteins 0.000 claims 10
- 239000002609 medium Substances 0.000 claims 10
- 230000003042 antagnostic effect Effects 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 8
- 230000003993 interaction Effects 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 230000004071 biological effect Effects 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 150000003384 small molecules Chemical class 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 208000023504 respiratory system disease Diseases 0.000 claims 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000003945 NF-kappa B Human genes 0.000 claims 2
- 108010057466 NF-kappa B Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000779 depleting effect Effects 0.000 claims 2
- 239000003480 eluent Substances 0.000 claims 2
- 238000001114 immunoprecipitation Methods 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims 1
- 229940122262 CD28 antagonist Drugs 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 108020002496 Lysophospholipase Proteins 0.000 claims 1
- 239000012826 P38 inhibitor Substances 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- -1 abatacept Chemical compound 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 229960003677 chloroquine Drugs 0.000 claims 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 229940076085 gold Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 229960004023 minocycline Drugs 0.000 claims 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 229960001967 tacrolimus Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65326005P | 2005-02-14 | 2005-02-14 | |
| US66749205P | 2005-04-01 | 2005-04-01 | |
| PCT/US2006/005111 WO2006088833A2 (en) | 2005-02-14 | 2006-02-14 | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008532936A JP2008532936A (ja) | 2008-08-21 |
| JP2008532936A5 true JP2008532936A5 (enExample) | 2009-04-02 |
Family
ID=36592866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007555332A Withdrawn JP2008532936A (ja) | 2005-02-14 | 2006-02-14 | インターロイキン−１７ｆ抗体及び他のｉｌ−１７ｆシグナル伝達拮抗物質並びにそれらの使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20090142806A1 (enExample) |
| EP (2) | EP2322553A3 (enExample) |
| JP (1) | JP2008532936A (enExample) |
| KR (1) | KR20070107703A (enExample) |
| CN (2) | CN101218254A (enExample) |
| AR (1) | AR052289A1 (enExample) |
| AU (1) | AU2006214473A1 (enExample) |
| BR (1) | BRPI0606991A2 (enExample) |
| CA (1) | CA2596509A1 (enExample) |
| CR (1) | CR9291A (enExample) |
| GT (1) | GT200600065A (enExample) |
| IL (1) | IL184933A0 (enExample) |
| MX (1) | MX2007009811A (enExample) |
| NO (1) | NO20074053L (enExample) |
| PE (1) | PE20061391A1 (enExample) |
| RU (1) | RU2007129263A (enExample) |
| TW (1) | TW200641353A (enExample) |
| WO (1) | WO2006088833A2 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| EP1629105B1 (en) | 2003-04-29 | 2010-09-01 | AVI BioPharma, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| AU2004259638C1 (en) | 2003-07-08 | 2018-12-20 | Novartis Pharma Ag | IL-17 A/F heterologous polypeptides and therapeutic uses thereof |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| BRPI0511952A (pt) | 2004-06-10 | 2008-01-29 | Zymogenetics Inc | receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14 |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| AU2006214384A1 (en) * | 2005-02-14 | 2006-08-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of IL-17F in diagnosis and therapy of airway inflammation |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| JP2009507023A (ja) | 2005-09-01 | 2009-02-19 | シェーリング コーポレイション | 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用 |
| US7622116B2 (en) | 2006-02-10 | 2009-11-24 | Zymogenetics, Inc. | Method of treating inflammation using soluble IL-17RCX4 |
| AU2007235212A1 (en) * | 2006-02-10 | 2007-10-18 | Zymogenetics, Inc. | Truncated IL-17RA soluble receptor and methods of using in inflammation |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| CA2646478A1 (en) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Antibodies that bind both il-17a and il-17f and methods of using the same |
| US7790163B2 (en) | 2006-03-10 | 2010-09-07 | Zymogenetics, Inc. | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| FR2908999B1 (fr) * | 2006-11-29 | 2012-04-27 | Biomerieux Sa | Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide. |
| FR2910324B1 (fr) * | 2006-12-21 | 2009-03-06 | Biomerieux Sa | Nouveau medicament pour le traitement d'un cancer gastrique |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
| JP5116842B2 (ja) * | 2007-04-27 | 2013-01-09 | ザイモジェネティクス， インコーポレイテッド | ＩＬ−１７ＡおよびＩｌ−１７Ｆの両方に結合する抗体ならびにそれを使用する方法 |
| AU2008266745B2 (en) * | 2007-06-20 | 2014-04-17 | Merck Sharp & Dohme Corp. | Joint destruction biomarkers for anti-IL-17A therapy of inflammatory joint disease |
| AU2008267151B2 (en) * | 2007-06-28 | 2014-02-20 | Neuramedy Co., Ltd. | Composition and method for treatment of autoimmune disease |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| EP2182943B1 (en) * | 2007-07-23 | 2016-10-26 | Janssen Biotech, Inc. | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| WO2009042162A2 (en) | 2007-09-25 | 2009-04-02 | Genzyme Corporation | Compositions and methods for inhibiting interleukin pathways |
| EP2106801A1 (en) | 2008-04-04 | 2009-10-07 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| SG10201608871XA (en) * | 2008-05-05 | 2016-12-29 | Novimmune Sa | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| AU2009273052B2 (en) | 2008-07-14 | 2015-09-17 | The University Of Tokyo | Aptamer against IL-17 and use thereof |
| TW201018482A (en) * | 2008-08-08 | 2010-05-16 | Glaxo Wellcome Mfg Pte Ltd | Novel treatment |
| EP2353004B1 (en) * | 2008-11-12 | 2018-01-03 | Yeda Research and Development Co. Ltd. | Diagnosis of multiple sclerosis |
| US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
| KR101579771B1 (ko) | 2009-03-05 | 2015-12-28 | 애브비 인코포레이티드 | Ｉｌ-17 결합 단백질 |
| CA2759848C (en) * | 2009-05-05 | 2018-12-04 | Novimmune S.A. | Anti-il-17f antibodies and methods of use thereof |
| WO2010142551A2 (en) * | 2009-06-12 | 2010-12-16 | Ablynx N.V. | Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family |
| CA2798149A1 (en) * | 2010-05-06 | 2011-11-10 | Singulex, Inc | Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis |
| EP2569431B1 (en) * | 2010-05-13 | 2015-09-23 | Sarepta Therapeutics, Inc. | Methods for identifying compounds which modulate interleukins 17 and 23 signaling activity |
| AU2011254557B2 (en) | 2010-05-20 | 2015-09-03 | Ablynx Nv | Biological materials related to HER3 |
| CN102380091A (zh) * | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
| DK2656070T3 (en) * | 2010-12-21 | 2016-06-13 | Max-Planck-Gesellschaft Zur Förderung Der Wss E V | Determination of a live recombined anti-mycobacterial vaccination efficacy |
| ES2632583T3 (es) | 2011-01-14 | 2017-09-14 | Ucb Biopharma Sprl | Anticuerpo que se une a IL-17A e IL-17F |
| US20120251524A1 (en) * | 2011-04-01 | 2012-10-04 | Baxter Healthcare S.A. | Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease |
| KR20140059168A (ko) | 2011-04-21 | 2014-05-15 | 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 | 시신경 척수염 치료용 조성물 및 치료 방법 |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
| CN103182072B (zh) * | 2011-12-27 | 2017-05-03 | 健能隆医药技术（上海）有限公司 | 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 |
| US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
| US8945553B2 (en) | 2012-05-22 | 2015-02-03 | Bristol-Myers Squibb Company | Bispecific antibodies to IL-23 and IL-17A/F |
| JP2015222174A (ja) * | 2012-09-13 | 2015-12-10 | 学校法人 久留米大学 | 炎症性疾患を処置するため薬剤のスクリーニング方法 |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| ES2682356T3 (es) | 2013-03-22 | 2018-09-20 | The University Of Tokyo | Aptámero para IL-17 y uso del mismo |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CN104311670B (zh) * | 2014-04-23 | 2017-05-17 | 哈尔滨博翱生物医药技术开发有限公司 | 针对IL‑17和TNFα的融合多肽及其应用 |
| CA2953216C (en) | 2014-06-04 | 2020-12-22 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| US12264344B2 (en) | 2014-08-19 | 2025-04-01 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| EP3247796A4 (en) | 2015-01-14 | 2018-07-11 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
| EP3250927B1 (en) * | 2015-01-28 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
| US9512229B2 (en) | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| EP3822367A1 (en) * | 2015-06-24 | 2021-05-19 | Oxford BioDynamics PLC | Detection processes using sites of chromosome interaction |
| CN105420237A (zh) * | 2015-09-08 | 2016-03-23 | 中国农业科学院兰州兽医研究所 | 靶向抑制小鼠白细胞介素17A基因的序列siRNA-180 |
| CN105420238A (zh) * | 2015-09-08 | 2016-03-23 | 中国农业科学院兰州兽医研究所 | 靶向抑制小鼠白细胞介素17A基因的序列siRNA-136 |
| ES2930351T3 (es) | 2016-04-15 | 2022-12-09 | Evive Biotechnology Shanghai Ltd | Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante |
| EP3452598A4 (en) * | 2016-05-06 | 2020-04-29 | Exicure, Inc. | LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| SG10202012839TA (en) | 2016-12-19 | 2021-01-28 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| IL297689A (en) * | 2020-04-30 | 2022-12-01 | Janssen Pharmaceutica Nv | Methods of identifying modulators of the il-17 pathway |
| CN113817058B (zh) * | 2021-09-30 | 2023-05-26 | 港科鹏禾生物(苏州)有限公司 | 一种抗人il-17rc的单克隆抗体及其应用 |
| CN116063493B (zh) * | 2022-07-22 | 2023-09-01 | 贵州省赛尔生物科技有限公司 | 包含抗体和间充质干细胞外泌体的药物组合物及其制备方法 |
| CN116024212A (zh) * | 2022-07-29 | 2023-04-28 | 硅羿科技（上海）有限公司 | 抑制IL-25基因表达的siRNA及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| GB2279725A (en) | 1993-07-09 | 1995-01-11 | Pall Corp | Combined check and pressure-relief valve |
| US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| US5516964A (en) | 1994-01-21 | 1996-05-14 | Sun Company, Inc. (R&M) | Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal |
| NZ306653A (en) * | 1995-03-23 | 1999-03-29 | Immunex Corp | Isolated dna il-17 receptors |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| US6902735B1 (en) * | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
| DK0929578T3 (da) * | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| US6635443B1 (en) * | 1997-09-17 | 2003-10-21 | Human Genome Sciences, Inc. | Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein |
| US6350892B1 (en) * | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| DE69935507T2 (de) | 1998-04-03 | 2007-12-06 | University Of Iowa Research Foundation | Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine |
| CA2328496C (en) * | 1998-05-15 | 2016-01-05 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
| KR20120091477A (ko) | 1999-03-25 | 2012-08-17 | 애보트 게엠베하 운트 콤파니 카게 | 사람 ｉｌ-12에 결합하는 사람 항체 및 이의 제조방법 |
| JP2003527104A (ja) * | 1999-12-23 | 2003-09-16 | ジェネンテック・インコーポレーテッド | Ｉｌ−１７相同的ポリペプチドとその治療上の用途 |
| US20040043397A1 (en) * | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| JP2004517918A (ja) * | 2000-10-18 | 2004-06-17 | イミュネックス・コーポレーション | Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法 |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| AU2004259638C1 (en) * | 2003-07-08 | 2018-12-20 | Novartis Pharma Ag | IL-17 A/F heterologous polypeptides and therapeutic uses thereof |
| BRPI0511952A (pt) * | 2004-06-10 | 2008-01-29 | Zymogenetics Inc | receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14 |
| CA2574848A1 (en) * | 2004-08-05 | 2006-12-21 | Wyeth | Antagonizing interleukin-21 receptor activity |
| AU2006214384A1 (en) * | 2005-02-14 | 2006-08-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of IL-17F in diagnosis and therapy of airway inflammation |
| ME02461B (me) | 2005-05-10 | 2017-02-20 | Incyte Holdings Corp | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih |
| TW200902064A (en) * | 2007-03-28 | 2009-01-16 | Wyeth Corp | Methods and compositions for modulating IL-17F/IL-17A biological activity |
-
2006
- 2006-02-14 WO PCT/US2006/005111 patent/WO2006088833A2/en not_active Ceased
- 2006-02-14 TW TW095104914A patent/TW200641353A/zh unknown
- 2006-02-14 AR ARP060100516A patent/AR052289A1/es unknown
- 2006-02-14 CA CA002596509A patent/CA2596509A1/en not_active Abandoned
- 2006-02-14 PE PE2006000175A patent/PE20061391A1/es not_active Application Discontinuation
- 2006-02-14 AU AU2006214473A patent/AU2006214473A1/en not_active Abandoned
- 2006-02-14 EP EP10176925A patent/EP2322553A3/en not_active Withdrawn
- 2006-02-14 MX MX2007009811A patent/MX2007009811A/es unknown
- 2006-02-14 BR BRPI0606991-6A patent/BRPI0606991A2/pt not_active IP Right Cessation
- 2006-02-14 CN CNA2006800125231A patent/CN101218254A/zh active Pending
- 2006-02-14 CN CN2011100361519A patent/CN102178953A/zh active Pending
- 2006-02-14 RU RU2007129263/13A patent/RU2007129263A/ru not_active Application Discontinuation
- 2006-02-14 EP EP06734991A patent/EP1848743A2/en not_active Ceased
- 2006-02-14 KR KR1020077018688A patent/KR20070107703A/ko not_active Withdrawn
- 2006-02-14 GT GT200600065A patent/GT200600065A/es unknown
- 2006-02-14 JP JP2007555332A patent/JP2008532936A/ja not_active Withdrawn
-
2007
- 2007-07-30 IL IL184933A patent/IL184933A0/en unknown
- 2007-08-07 CR CR9291A patent/CR9291A/es not_active Application Discontinuation
- 2007-08-07 NO NO20074053A patent/NO20074053L/no not_active Application Discontinuation
-
2008
- 2008-08-21 US US12/196,117 patent/US20090142806A1/en not_active Abandoned
-
2010
- 2010-06-30 US US12/827,199 patent/US20110033451A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008532936A5 (enExample) | ||
| RU2007129263A (ru) | Антитела к интерлейкину-17f и другие антагонисты опосредуемой il-17f передачи сигналов и их применение | |
| Menegatti et al. | Anti-TNF therapy in spondyloarthritis and related diseases, impact on the immune system and prediction of treatment responses | |
| Hawkes et al. | Psoriasis pathogenesis and the development of novel targeted immune therapies | |
| Brzustewicz et al. | The role of cytokines in the pathogenesis of rheumatoid arthritis–Practical and potential application of cytokines as biomarkers and targets of personalized therapy | |
| Semerano et al. | Novel immunotherapeutic avenues for rheumatoid arthritis | |
| Williams et al. | Cytokine inhibitors in rheumatoid arthritis and other autoimmune diseases | |
| Gaffen et al. | IL-23-IL-17 immune axis: discovery, mechanistic understanding, and clinical testing | |
| Hu et al. | The IL‐17 pathway as a major therapeutic target in autoimmune diseases | |
| US6183951B1 (en) | Methods of diagnosing clinical subtypes of crohn's disease with characteristic responsiveness to anti-Th1 cytokine therapy | |
| US20080031882A1 (en) | Methods of modulating IL-22 and IL-17 | |
| Kupetsky et al. | Anti-cytokine therapy in the treatment of psoriasis | |
| AU2016210996B2 (en) | Therapeutic target and biomarker in IBD | |
| O’Shea et al. | In search of magic bullets: the golden age of immunotherapeutics | |
| JP2007515942A5 (enExample) | ||
| CA2819538A1 (en) | Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle. | |
| Yang et al. | The star target in SLE: IL-17 | |
| IL298626A (en) | Cytokine conjugates | |
| ZA200509143B (en) | GITR ligand and GITR ligand-related molecules and antibodies and uses thereof | |
| WO2016191289A2 (en) | Biomarker for inflammatory disorders and uses thereof | |
| Taylor et al. | Aetiopathology of rheumatoid arthritis | |
| WO2024102387A2 (en) | Fusion polypeptides and formulations thereof | |
| Yeo | Characterisation of cytokine expression in early synovitis and established rheumatoid arthritis | |
| CN116144668A (zh) | 人il-1r1基因、蛋白、同源二聚体蛋白质与用途 | |
| Alho | Mechanisms of post-transplant obliterative bronchiolitis: Study in a porcine heterotopic bronchial transplantation model |